JAIME SCHNEIDER

Dr. JAIME SCHNEIDER

Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2023 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
JAIME SCHNEIDERJAIME SCHNEIDER
JAIME SCHNEIDER
JLJessica J. Lin
Jessica J. Lin
ASAlice T. Shaw
Alice T. Shaw

15 April 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
APAparna R. Parikh
Aparna R. Parikh
AMAmirkasra Mojtahed
Amirkasra Mojtahed
JAIME SCHNEIDERJAIME SCHNEIDER
JAIME SCHNEIDER
KKKatie Kanter
Katie Kanter
ESEmily E. Van Seventer
Emily E. Van Seventer
RCRyan B. Corcoran
Ryan B. Corcoran
Purpose: ctDNA offers a promising, noninvasive approach to monitor therapeutic efficacy in real-time. We explored whether the quantitative percent change in ctDNA early after therapy initiation can predict treatment response and progression-free survival (PFS) in patients with metastatic gastrointestinal cancer. Experimental Design: A total of 138 patients with metastatic gastrointestinal cancers and tumor profiling by next-generation sequencing had serial blood draws pretreatment and at scheduled intervals during therapy. ctDNA was assessed using individualized droplet digital PCR measuring the mutant allele fraction in plasma of mutations identified in tumor biopsies. ctDNA changes were correlated with tumor markers and radiographic response. Results: A total of 138 patients enrolled. A total of 101 patients were evaluable for ctDNA and 68 for tumor markers at 4 weeks. Percent change of ctDNA by 4 weeks predicted partial response (PR, P < 0.0001) and clinical benefit [CB: PR and stable disease (SD), P < 0.0001]. ctDNA decreased by 98% (median) and >30% for all PR patients. ctDNA change at 8 weeks, but not 2 weeks, also predicted CB (P < 0.0001). Four-week change in tumor markers also predicted response (P = 0.0026) and CB (P = 0.022). However, at a clinically relevant specificity threshold of 90%, 4-week ctDNA change more effectively predicted CB versus tumor markers, with a sensitivity of 60% versus 24%, respectively (P = 0.0109). Patients whose 4-week ctDNA decreased beyond this threshold (≥30% decrease) had a median PFS of 175 days versus 59.5 days (HR, 3.29; 95% CI, 1.55–7.00; P < 0.0001). Conclusions: Serial ctDNA monitoring may provide early indication of response to systemic therapy in patients with metastatic gastrointestinal cancer prior to radiographic assessments and may outperform standard tumor markers, warranting further evaluation.

23 August 2024 in The Oncologist
Verified
Journal Article
Open access
MBMary Boulanger
Mary Boulanger
JAIME SCHNEIDERJAIME SCHNEIDER
JAIME SCHNEIDER
JLJessica J Lin
Jessica J Lin
ROS1 gene fusions are an established oncogenic driver comprising 1%-2% of non–small cell lung cancer (NSCLC). Successful targeting of ROS1 fusion oncoprotein with oral small-molecule tyrosine kinase inhibitors (TKIs) has revolutionized the treatment landscape of metastatic ROS1 fusion-positive (ROS1+) NSCLC and transformed outcomes for patients. The preferred Food and Drug Administration-approved first-line therapies include crizotinib, entrectinib, and repotrectinib, and currently, selection amongst these options requires consideration of the systemic and CNS efficacy, tolerability, and access to therapy. Of note, resistance to ROS1 TKIs invariably develops, limiting the clinical benefit of these agents and leading to disease relapse. Progress in understanding the molecular mechanisms of resistance has enabled the development of numerous next-generation ROS1 TKIs, which achieve broader coverage of ROS1 resistance mutations and superior CNS penetration than first-generation TKIs, as well as other therapeutic strategies to address TKI resistance. The approach to subsequent therapy depends on the pace and pattern of progressive disease on the initial ROS1 TKI and, if known, the mechanisms of TKI resistance. Herein, we describe a practical approach for the selection of initial and subsequent therapies for metastatic ROS1+ NSCLC based on these clinical considerations. Additionally, we explore the evolving evidence for the optimal treatment of earlier-stage, non–metastatic ROS1+ NSCLC, while, in parallel, highlighting future research directions with the goal of continuing to build on the tremendous progress in the management of ROS1+ NSCLC and ultimately improving the longevity and well-being of people living with this disease.

6 February 2025 in Cell
Verified
Journal Article
Closed access
JAIME SCHNEIDERJAIME SCHNEIDER
JAIME SCHNEIDER
KKKiran Kurmi
Kiran Kurmi
YDYutong Dai
Yutong Dai
IDIshita Dhiman
Ishita Dhiman
SJShakchhi Joshi
Shakchhi Joshi
MHMarcia C. Haigis
Marcia C. Haigis

20 May 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NCNoura J. Choudhury
Noura J. Choudhury
JAIME SCHNEIDERJAIME SCHNEIDER
JAIME SCHNEIDER
TPTejas Patil
Tejas Patil
VZViola Weijia Zhu
Viola Weijia Zhu
DGDebra A. Goldman
Debra A. Goldman
ADAlexander Drilon
Alexander Drilon

3 November 2023 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
JAIME SCHNEIDERJAIME SCHNEIDER
JAIME SCHNEIDER
KSKhvaramze Shaverdashvili
Khvaramze Shaverdashvili
MMMari Mino-Kenudson
Mari Mino-Kenudson
SDSubba R. Digumarthy
Subba R. Digumarthy
ADAndrew Do
Andrew Do
JLJessica J. Lin
Jessica J. Lin
Acquired drug resistance remains a major problem across oncogene-addicted cancers. Elucidation of mechanisms of resistance can inform rational treatment strategies for patients relapsing on targeted therapies while offering insights into tumor evolution. Here, we report acquired MET amplification as a resistance driver in a ROS1-rearranged lung adenocarcinoma after sequential treatment with ROS1 inhibitors. Subsequent combination therapy with lorlatinib plus capmatinib, a MET-selective inhibitor, induced intracranial and extracranial tumor response. At relapse, sequencing of the resistant tumor revealed a MET D1246N mutation and loss of MET amplification. We performed integrated molecular analyses of serial tumor and plasma samples, unveiling dynamic alterations in the ROS1 fusion driver and MET bypass axis at genomic and protein levels and the emergence of polyclonal resistance. This case illustrates the complexity of longitudinal tumor evolution with sequential targeted therapies, highlighting challenges embedded in the current precision oncology paradigm and the importance of developing approaches that prevent resistance.